Gavi, the Vaccine Alliance has a formal process for evaluating its organisational and programmatic activities that is guided by an evaluation policy.
Gavi, the Vaccine Alliance has a formal process for evaluating its organisational and programmatic activities that is guided by an evaluation policy.
Gavi undertakes centralised and decentralised evaluations, which include the following types of evaluations corresponding to Gavi functions and programmes1:
Strategic evaluations: Assess the quality of design, extent of implementation, results and sustainability of specific strategies, policies, processes, frameworks and models adopted by Gavi. Strategic evaluations are in most cases centralised.
Thematic evaluations: Evaluation of a selection of interventions, all of which address a specific priority that cuts across countries, regions, and sectors. Thematic evaluations are in most cases centralised.
Country and Programme evaluations: Evaluation to assess design, programmatic results and sustainability of Gavi supported programmes in specific countries. Country and Programme evaluations are in most cases decentralised.2
The Evaluation Advisory Committee (EAC) established by the Board of the Gavi Alliance supports the Board in fulfilling its oversight responsibilities in respect to the management of Gavi’s evaluation activities (as defined in the Gavi Alliance Evaluation Policy).
Gavi, the Vaccine Alliance commissioned a prospective independent, multi-year evaluation of its CCEOP investment to a coalition led by JSI Research & Training Institute, Inc.(JSI) with Stat View International (Guinea), JaRco Consulting (Kenya…
Gavi, the Vaccine Alliance, commissioned an independent outcome and impact evaluation of Gavi’s Pneumococcal Conjugate Vaccine Advance Market Commitment (PCV AMC) led by Dalberg.
This report presents the findings from the ‘Evaluation of the Gavi Supply and Procurement Strategy, 2016-2020’. The evaluation was conducted by CEPA in 2020, with the purpose to generate evidenced-based data and learning to inform the Gavi Supply…
Gavi, the Vaccine Alliance, appointed Cambridge Economic Policy Associates (CEPA) to conduct an evaluation of Gavi’s Eligibility and Transition and Co-financing Policies.
This report presents the main findings from an evaluation of Gavi’s support to civil society organisations (CSOs) during the period 2011 to 2017. The evaluation was conducted by Itad in 2018.
The 2008 HSS tracking study is complementary to the HSS evaluation, providing a more in depth country perspective that helped highlight implementation issues in 6 countries.
Gavi, the Vaccine Alliance launched a prospective evaluation to collect real-time data on immunisation programmes, vaccine-related issues and the contribution of Alliance support in four countries.
In 2018 the Gavi Evaluation Unit commissioned an independent review of Gavi’s Performance Based Funding (PBF) component of its Health System Strengthening (HSS) support to countries. This review was conducted by Duke University between April and…
An evaluation is currently under way to assess the relevance, effectiveness and efficiency of technical assistance to countries through Gavi’s partners’ engagement framework (PEF).
This report presents the main findings from an evaluation of Gavi’s support to Albania and its transition after funding ended. The evaluation was conducted by the Curatio International Foundation in 2015.
This report presents the lessons learnt and recommendations from an evaluation of Gavi’s support to Bosnia and Herzegovina and its transition after funding ended. The evaluation was conducted by the Curatio International Foundation in 2014.
This report presents the lessons learnt and recommendations from an independent evaluation of the Gavi co-financing policy conducted by the Norwegian Institute of Public Health in 2014.
This report presents the findings and lessons from an evaluation of the Gavi-Government of China Hepatitis B vaccination programme. The evaluation was conducted in 2012 by Abt Associates.
This report presents the findings of the Process and Design Evaluation for the Pilot Advance Market Commitment (AMC) for Pneumococcal Vaccines. This evaluation was conducted in 2012 by Dalberg Global Development Advisors.
This report presents the findings of the Outcomes and Impact evaluation for the Pilot Advance Market Commitment (AMC) for Pneumococcal Vaccines. This evaluation was conducted in 2015 by The Boston Consulting Group.
This report presents the findings and lessons from a review of Gavi’s support to civil society organisations undertaken by Cambridge Economic Policy Associates.
The June 2011 evaluation of the International Finance Facility for Immunisation (IFFIm) assesses whether the IFF concept is proven and whether the IFFIm pilot has worked.
The Baseline Study for the pneumococcal vaccine Advance Market Commitment establishes the environment prior to the AMC as a basis for future evaluations.
The Gavi second evaluation report sets out the main findings of an independent assessment of the Vaccine Alliance's achievements in Phase II (2007-2010).
The Gavi first evaluation report sets out the main findings of an independent assessment of the Vaccine Alliance's achievements in Phase I (2000-2005).
As part of a broader review of the Data Strategic Focus Area (SFA) within Gavi 4.0 and in preparation for new funding allocations for DHIS2 in alignment with the Gavi 5.0 Strategy, Gavi has commissioned HealthEnabled to conduct this Look Back and Look Forward Review to document lessons learned from past Gavi investments and align future activities with the Digital Health Information Strategy and Gavi 5.0 focus on zero-dose children.
Gavi, the Vaccine Alliance appointed the Infectious Diseases Research Collaboration (IDRC), Uganda, to conduct an evaluation of the drivers of urban immunization in Uganda with Kampala City as case study.
A report from UNICEF and Gavi, the Vaccine Alliance compiling the good practices and lessons learned from countries implementing real-time monitoring for immunisation campaigns.
Exploring current approaches to leaving no child behind with immunisation by harnessing geospatial technologies and GIS to improve immunisation coverage and equity in low- and middle-income countries.
This evaluation covers the implementation of the eighth Memorandum of Understanding (MOU8; 2016-2020) between Gavi, the Vaccine Alliance, and UNICEF Supply Division (SD).
